Hier finden Sie die direkt aus den bewilligten UroAgeCare-Projekten hervorgegangenen Publikationen.  

2022

• Klümper N, Hölzel M, Eckstein M et.al: Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance. Clin Cancer Res. 2022 Dec 19;CCR-22-1764. doi: 10.1158/1078-0432.CCR-22-1764. Online ahead of print.  Weblinks: https://pubmed.ncbi.nlm.nih.gov/36534531/; https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-1764/711754/Membranous-NECTIN-4-expression-frequently

2024

• Klümper N, Tran NK, Zschaebitz S, Hahn O, Zengerling F, Nagy D, et al. Occur-rence of NECTIN4 amplification in solid tumors and enfortumab vedotin response in metastatic urothelial cancer. JCO [Internet]. 2024 Feb [cited 2024 Feb 5];42(4_suppl):673–673. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2024.42.4_suppl.673
• Klümper N, Vera-Badillo FE, Eckstein M, Hadaschik B, Grünwald V. Re: Enfor-tumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. Eur Urol. 2024 Apr 9;S0302-2838(24)02257-7
• Klümper N, Eckstein M. Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer. European Urology Focus [In-ternet]. 2024 Apr 16 [cited 2024 Apr 17]; Available from: https://www.sciencedirect.com/science/article/pii/S2405456924000531